Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 458.05, up by 5.05 points or 1.11% from its previous closing of Rs. 453.00 on the BSE.

The scrip opened at Rs. 454.00 and has touched a high and low of Rs. 460.15 and Rs. 452.40 respectively. So far 63532 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 631.00 on 23-May-2017 and a 52 week low of Rs. 433.15 on 14-Aug-2017.

Last one week high and low of the scrip stood at Rs. 489.70 and Rs. 434.80 respectively. The current market cap of the company is Rs. 108689.34 crore.

The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.55% and 13.07% respectively.

Sun Pharmaceutical Industries’ wholly owned subsidiary companies have received approval from the US Food and Drug Administration (USFDA) for YONSA (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Earlier, the company had acquired YONSA from Churchill Pharmaceuticals and will commercialize YONSA in the US.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.